Improving Patient Access to Therapies for TCL: A Resource Guide

Download this PDF guide to best practices for optimal team management of patients with T-cell lymphomas with biomarker-driven therapies.
Talha Khan, PharmD, BCOP
Format: Adobe Acrobat (.pdf)
File Size: 425 KB
Released: December 6, 2021

Information on this Educational Activity

Faculty

Talha Khan, PharmD, BCOP

Hematology/Oncology Team Lead
Clinical Pharmacist

Robert H. Lurie Comprehensive Cancer Center
Northwestern Memorial Hospital
Chicago, Illinois

Talha Khan, PharmD, BCOP, has no relevant conflicts of interest to disclose.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Kyowa Kirin, Inc.
Seagen Inc.
Takeda Oncology

Related Content

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 27, 2022

Downloadable slideset from a local live webinar developed by lymphoma experts with guidance on the management of indolent lymphomas

Elizabeth Brém, MD Christopher R. Flowers, MD, MS Released: June 21, 2022

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

Updated data for epcoritamab + rituximab and lenalidomide in relapsed/refractory follicular lymphoma from EPCORE NHL-2, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings